Cell Source, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cell Source, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.51M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($5.32M) | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | ($5.17M) | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | ($5.47M) | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | ($4.56M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($4.48M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.12M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.08M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($967.8K) | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | ($2.50M) | Jul 25, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.84M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($4.33M) | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | ($4.18M) | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | ($4.02M) | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | ($3.64M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($3.81M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.01M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.29M) | Apr 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.94M | Aug 8, 2023 |
| FY2022 | Dec 31, 2021 | $1.27M | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | $834.9K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.46M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $274.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $637.3K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $554.2K | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | $392.9K | Jul 25, 2018 |
| FY2015 | Dec 31, 2014 | $806.2K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $351.5K | Mar 13, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.28M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $815.9K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $951.8K | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | $1.10M | Jul 25, 2018 |
| FY2015 | Dec 31, 2014 | $2.24M | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $319.9K | Mar 13, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.68M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($2.35M) | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | ($3.14M) | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | ($3.38M) | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | ($2.77M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($2.59M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.00M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.29M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($1.49M) | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | ($2.00M) | Jul 25, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2014 | $2.6K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Mar 13, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $286.5K | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | $195.2K | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | $409.8K | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | $313.8K | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | $452.3K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $114.8K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $65.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $531.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $211.1K | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | $214.8K | Jul 25, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $18.82M | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | $15.81M | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | $13.04M | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | $10.14M | Aug 8, 2023 |
| FY2020 | Dec 31, 2020 | $8.40M | Apr 15, 2021 |
| FY2020 | Dec 31, 2019 | $5.86M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $4.99M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.09M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.45M | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | $5.97M | Jul 25, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($18.54M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($15.61M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2022 | ($12.63M) | Apr 7, 2026 |
| FY2023 | Dec 31, 2021 | ($9.83M) | Jun 24, 2024 |
| FY2022 | Dec 31, 2020 | ($7.95M) | Aug 8, 2023 |
| FY2021 | Dec 31, 2019 | ($5.74M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | ($4.92M) | Apr 15, 2021 |
| FY2019 | Jan 1, 2018 | ($4.56M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.56M) | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | ($6.24M) | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($46.18M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($41.67M) | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | ($36.35M) | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | ($31.18M) | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | ($25.71M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($21.15M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($16.67M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($14.55M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($11.47M) | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | ($10.50M) | Jul 25, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $222.7K | Aug 8, 2023 |
| FY2022 | Dec 31, 2021 | $93.1K | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | $241.6K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $27.9K | Apr 15, 2021 |
| FY2020 | Dec 31, 2018 | $18.9K | Apr 15, 2021 |
| FY2018 | Dec 31, 2017 | $371.0K | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $3.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $6.9K | Jul 25, 2018 |
| FY2017 | Dec 31, 2014 | $19.5K | Jul 25, 2018 |
| FY2015 | Dec 31, 2013 | $28.9K | Apr 14, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $50.0K | Jul 25, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 45.04M | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | 39.83M | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | 36.08M | Jun 24, 2024 |
| FY2022 | Dec 31, 2021 | 34.36M | Aug 8, 2023 |
| FY2021 | Dec 31, 2020 | 32.54M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 27.08M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 26.08M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 25.35M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 24.68M | Jul 25, 2018 |
| FY2017 | Dec 31, 2015 | 23.93M | Jul 25, 2018 |